var data={"title":"Loratadine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Loratadine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6481?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=loratadine-drug-information\" class=\"drug drug_general\">see &quot;Loratadine: Drug information&quot;</a> and <a href=\"topic.htm?path=loratadine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Loratadine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190023\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alavert [OTC];</li>\n      <li>Allergy Relief For Kids [OTC] [DSC];</li>\n      <li>Allergy Relief [OTC];</li>\n      <li>Allergy [OTC];</li>\n      <li>Childrens Loratadine [OTC];</li>\n      <li>Claritin Allergy Childrens [OTC];</li>\n      <li>Claritin Childrens [OTC];</li>\n      <li>Claritin Reditabs [OTC];</li>\n      <li>Claritin [OTC];</li>\n      <li>Loradamed [OTC];</li>\n      <li>Loratadine Childrens [OTC];</li>\n      <li>Loratadine Hives Relief [OTC] [DSC];</li>\n      <li>QlearQuil 24 Hour Relief [OTC] [DSC];</li>\n      <li>Triaminic Allerchews [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190024\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Loratadine;</li>\n      <li>Claritin&reg;;</li>\n      <li>Claritin&reg; Kids</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059881\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihistamine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059874\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=loratadine-drug-information\" class=\"drug drug_general\">see &quot;Loratadine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic symptoms/rhinitis:</b> Oral</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;6 years: Oral liquid or chewable tablet: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral liquid, capsule, tablet, or chewable tablet: 10 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dispersible tablet: 5 mg twice daily or 10 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic idiopathic urticaria:</b> Limited data available (Kliegman 2011; Simons 1994):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 12 years: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 10 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic symptoms/rhinitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral liquid, capsule, tablet, or chewable tablet: 10 mg daily once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dispersible tablet: 5 mg twice daily or 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling, however, the following recommendations have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: No dosage adjustment necessary for any degree of renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: 10 mg every 24 to 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: 10 mg every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): No dosage adjustment necessary if clearance is 2,000 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190002\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Loratadine: 5 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loratadine Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loratadine Hives Relief: 5 mg/5 mL (120 mL [DSC]) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief For Kids: 5 mg/5 mL (120 mL [DSC]) [contains propylene glycol, sodium benzoate; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Loratadine: 5 mg/5 mL (120 mL) [fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Loratadine: 5 mg/5 mL (120 mL) [alcohol free, dye free; contains propylene glycol, sodium benzoate, sodium metabisulfite; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin: 5 mg/5 mL (60 mL [DSC], 120 mL [DSC], 150 mL [DSC]) [alcohol free, color free, dye free, sugar free; contains edetate disodium, propylene glycol, sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin Allergy Childrens: 5 mg/5 mL (240 mL) [alcohol free, dye free, sugar free; contains edetate disodium, propylene glycol, sodium benzoate, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loratadine Childrens: 5 mg/5 mL (120 mL) [sugar free; contains polyethylene glycol, propylene glycol, sodium benzoate, sodium metabisulfite; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alavert: 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loradamed: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QlearQuil 24 Hour Relief: 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin: 5 mg [contains aspartame, fd&amp;c blue #2 aluminum lake; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin Childrens: 5 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alavert: 10 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alavert: 10 mg [contains aspartame; citrus flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy: 10 mg [DSC] [contains aspartame; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief: 10 mg [DSC] [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief: 10 mg [contains aspartame; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin Reditabs: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triaminic Allerchews: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189988\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059886\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer without regard to meals </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rapidly disintegrating tablet: Place rapidly disintegrating tablet on the tongue; tablet disintegration occurs rapidly; may administer with or without water</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190019\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rapidly-disintegrating tablets: Use within 6 months of opening foil pouch, and immediately after opening individual tablet blister. Store in a dry place.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059885\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Symptomatic relief of nasal and non-nasal symptoms of allergic rhinitis (OTC product: FDA approved in ages &ge;2 years and adults); has also been used for the treatment of chronic idiopathic urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6699703\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin may be confused with clarithromycin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claritin (loratadine) may be confused with Claritin Eye (ketotifen)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lorcaserin hydrochloride may be confused with lorcaserin hydrochloride</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190073\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness (adults), fatigue, headache (adults), malaise (children 6 to 12 years), nervousness (children 6 to 12 years), voice disorder (children 6 to 12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (children 2 to 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (children 6 to 12 years), stomatitis (children 2 to 5 years), xerostomia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection (children 2 to 5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Hyperkinesia (children 6 to 12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis (children 6 to 12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis (children 2 to 5 years), flu-like symptoms (children 2 to 5 years), pharyngitis (children 2 to 5 years), upper respiratory tract infection (children 6 to 12 years), wheezing (children 6 to 12 years), </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal lacrimation, agitation, alopecia, altered micturition, altered salivation, amnesia, anaphylaxis, angioedema, anorexia, arthralgia, back pain, blepharospasm, blurred vision, breast hypertrophy, bronchospasm, chest pain, confusion, depression, dizziness, dysgeusia, dysmenorrhea, dyspnea, erythema multiforme, hemoptysis, hepatic insufficiency, hepatic necrosis, hepatitis, hypermenorrhea, hypotension, impotence, insomnia, irritability, jaundice, lack of concentration, mastalgia, migraine, nausea, nightmares, palpitations, paresthesia, peripheral edema, pruritus, purpura, rigors, seizure, skin photosensitivity, supraventricular tachycardia, syncope, tachycardia, thrombocytopenia, tremor, urine discoloration, urticaria, vaginitis, vertigo, vomiting, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190007\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to loratadine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189992\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Hepatic impairment increases systemic exposure. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28473558\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in this age group. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA notes that there are no approved OTC uses for these products in pediatric patients &lt;2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2012; FDA 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190063\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189997\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12563&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the sedative effect of Antihistamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190020\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food increases bioavailability and delays peak. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12881433\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Maternal use of loratadine has not been associated with an increased risk of major malformations. Loratadine may be used for the treatment of allergic rhinitis and urticaria during pregnancy (NAEPP 2005; Wallace 2008; Zuberbier 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059880\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Improvement in signs and symptoms of allergic rhinitis or chronic idiopathic urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189991\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Long-acting tricyclic antihistamine with selective peripheral histamine H<sub>1</sub>-receptor antagonistic properties</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190006\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The pharmacokinetic profile of children 2 to 12 years is similar to that of adults (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 1-3 hours (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 8-12 hours (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &gt;24 hours (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; food increases total bioavailability (AUC) by 40% to 48% (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 119 L/kg (Haria 1994); binds preferentially to peripheral nervous system H<sub>1</sub> receptors; no appreciable entry into CNS (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 97% to 99% (loratadine), 73% to 76% (metabolite) (Haria 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via CYP2D6 and 3A4 to active metabolite (descarboethoxyloratadine) (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 8.4 hours (range: 3 to 20 hours) (loratadine), 28 hours (range: 8.8 to 92 hours) (metabolite) (Claritin prescribing information 2000); hepatic impairment: 24 hours (loratadine), 37 hours (metabolite) (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Loratadine: 1.3 hours (loratadine), 2.3 hours (metabolite) (Claritin prescribing information 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (40%) and feces (40%) as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190009\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Claritin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $22.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Loratadine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $17.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Claritin Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Claritin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (20): $19.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Claritin Allergy Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (240 mL): $17.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Alavert Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Claritin Reditabs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (10): $9.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $22.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Triaminic Allerchews Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (8): $5.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Claritin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (70): $36.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Loratadine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $79.95</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190012\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerotina (AR);</li>\n      <li>Alaron (BD);</li>\n      <li>Albatrina (MX);</li>\n      <li>Alerfast (PE);</li>\n      <li>Alergit (EC);</li>\n      <li>Alernitis (ID);</li>\n      <li>Alert (BD);</li>\n      <li>Alledine (AU);</li>\n      <li>Allereze (AU);</li>\n      <li>Allergyn (SG);</li>\n      <li>Allergyx (IL);</li>\n      <li>Allerta (PH);</li>\n      <li>Allertyn (HK);</li>\n      <li>Allohex (ID);</li>\n      <li>Allor (HK);</li>\n      <li>Alloris (SG);</li>\n      <li>Ardin (SG);</li>\n      <li>Avotyne (MY);</li>\n      <li>Bonalerg (GT);</li>\n      <li>Caradine (TH);</li>\n      <li>Carin (MY);</li>\n      <li>Carinose (TH);</li>\n      <li>Civeran (ES);</li>\n      <li>Cladin (BD);</li>\n      <li>Clalodine (TH);</li>\n      <li>Clara (QA, SA);</li>\n      <li>Claratyne (AU, CY, NZ);</li>\n      <li>Clarid (TH);</li>\n      <li>Clarihist (PH);</li>\n      <li>Clarin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Clarinese (ZA);</li>\n      <li>Claritin (BB, BR, ID, PH);</li>\n      <li>Claritine (AE, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, EE, EG, ET, GH, GM, GN, GY, HR, HU, IQ, IR, JM, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PK, PL, PT, RO, RU, SA, SC, SD, SI, SK, SL, SN, SR, SY, TN, TR, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Clarityn (AT, DK, FI, GB, IE, IS, IT, NO, SE);</li>\n      <li>Clarityne (AR, CL, CN, CO, CR, DO, ES, FR, GR, GT, HK, HN, KR, LK, MX, MY, NI, PA, PE, PY, SV, TH, TW, UY, VE, VN);</li>\n      <li>CPLoradine (HK);</li>\n      <li>Cronitin (ID);</li>\n      <li>Curyken (MX);</li>\n      <li>Dimegan (MX);</li>\n      <li>Dymaten (MX);</li>\n      <li>Efectine (MX);</li>\n      <li>Erolin (BM, BS, BZ, GY, JM, SR, TT, UA, VN);</li>\n      <li>Ezede (SG);</li>\n      <li>Finska (TW);</li>\n      <li>Frenaler (CL);</li>\n      <li>Fristamin (IT);</li>\n      <li>Genadine (TW);</li>\n      <li>Glora (QA);</li>\n      <li>Halodin (TH);</li>\n      <li>Histaclar (IE);</li>\n      <li>Histafax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Inigrin (MX);</li>\n      <li>J-Tadine (KR);</li>\n      <li>Klaratyn (UA);</li>\n      <li>Klarihist (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Klinset (ID);</li>\n      <li>Laredine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Laritol (MX);</li>\n      <li>Larotin (EC);</li>\n      <li>Laura (ZA);</li>\n      <li>Lertamine (MX);</li>\n      <li>Lisino (DE);</li>\n      <li>Lobeta (DE);</li>\n      <li>Lodin (BD);</li>\n      <li>Lohist (BH, JO, KW, SA);</li>\n      <li>Lora (TW);</li>\n      <li>Lora-Lich (DE);</li>\n      <li>Lora-Tabs (NZ);</li>\n      <li>Lorabasics (DE);</li>\n      <li>Loraclar (DE);</li>\n      <li>Loraclear Hayfever Relief (NZ);</li>\n      <li>Loradad (LB);</li>\n      <li>Loraday (ET);</li>\n      <li>Loraderm (DE);</li>\n      <li>Loradin (HK);</li>\n      <li>Loradine (ET);</li>\n      <li>Lorahist (PH);</li>\n      <li>Lorakine (QA);</li>\n      <li>Loralerg (DE);</li>\n      <li>Lorano (AU, DE, PH, ZA);</li>\n      <li>Lorastine (IL);</li>\n      <li>Lorastyne (AU);</li>\n      <li>Lorat (IE);</li>\n      <li>Loratadura (DE);</li>\n      <li>Loratan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Loratin (AE, QA, TZ, ZW);</li>\n      <li>Loraton (HK);</li>\n      <li>Loratrim (IL);</li>\n      <li>Loratyne (PH);</li>\n      <li>Lordamin (TH);</li>\n      <li>Lorfast (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Lorid (LK);</li>\n      <li>Loridin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Lorihis (ID);</li>\n      <li>Lorimox (MX);</li>\n      <li>Lorin (IN);</li>\n      <li>Lorine (BH, JO, KW);</li>\n      <li>Lorita (HK, TH);</li>\n      <li>Loryzan (UA);</li>\n      <li>Lotan (MX);</li>\n      <li>Lotarin (TW);</li>\n      <li>Mosedin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Nasaler (PE);</li>\n      <li>Neoalexil (MX);</li>\n      <li>Neoday (QA);</li>\n      <li>Noseling (TW);</li>\n      <li>NT-Alergi (HK);</li>\n      <li>Nufalora (ID);</li>\n      <li>Orin (LK);</li>\n      <li>Pylor (ID);</li>\n      <li>Rahistin (ID);</li>\n      <li>Restamin (QA);</li>\n      <li>Restamine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Ridamin (SG);</li>\n      <li>Rinityn (PH, SG);</li>\n      <li>Rityne (TH);</li>\n      <li>Rotifar (MY);</li>\n      <li>Sanelor (LU);</li>\n      <li>Sensibit (MX);</li>\n      <li>Sensibit XP (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Sinaler (PY);</li>\n      <li>Soneryl (ID);</li>\n      <li>Sunadine (MY);</li>\n      <li>Tidilor (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Tinnic (ID);</li>\n      <li>Tricel (EC);</li>\n      <li>Vincidal (MX);</li>\n      <li>XSM (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Children's Claritin syrup (loratadine) [prescribing information].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claritin tablets, syrup, and rapidly-disintegrating tablets (loratadine) [prescrbing information]. Kenilworth, NJ; Schering Corporation; July 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claritin Reditabs (loratadine) [prescribing information]. Memphis, TN: MSD Consumer Care, Inc.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claritin tablets (loratadine) [prescribing information].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claritin-D12 (loratadine) [prescribing information].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claritin-D24 (loratadine) [prescribing information].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Five things physicians and patients should question. April 4, 2012. Available at http://www.choosingwisely.org/choosing-wisely-five-things-physicians-and-patients-should-question-press-release-april-4-2012/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). OTC cough and cold products: not for infants and children under 2 years of age. January 17, 2008. Available at <a href=\"http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm\" target=\"_blank\">http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm</a>. Last accessed January 29, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. <i>Drugs</i>. 1994 ;48(4):617-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/7528133/pubmed\" target=\"_blank\" id=\"7528133\">7528133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilbert J, Radwanski E, Affrime MB, et al, &quot;Excretion of Loratadine in Human Breast Milk,&quot; <i>J Clin Pharmacol</i>, 1988, 28(3):234-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/2966185/pubmed\" target=\"_blank\" id=\"2966185\">2966185</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin CC, Radwanski E, Affrime M, et al, &ldquo;Pharmacokinetics of Loratadine in Pediatric Subjects,&rdquo; <i>Am J Therapeut</i>, 1995, 2:504-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/11850699 /pubmed\" target=\"_blank\" id=\"11850699 \">11850699 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luck JC and Evrard HM, &ldquo;Atrial Fibrillation Associated With Loratadine Use,&rdquo; <i>J Allergy Clin Immunol</i>, 1995, 95(2):282.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lutsky BN, Klose P, Melon J, et al, &ldquo;A Comparative Study of the Efficacy and Safety of Loratadine Syrup and Terfenadine Suspension in the Treatment of 3 to 6 Year Old Children With Seasonal Allergic Rhinitis,&rdquo; <i>Clin Ther</i>, 1993, 15(5):855-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/8269452/pubmed\" target=\"_blank\" id=\"8269452\">8269452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/3928731/pubmed\" target=\"_blank\" id=\"3928731\">3928731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute and National Asthma Education and Prevention Program Asthma and Pregnancy Working Group, &quot;NAEPP Expert Panel Report. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment - 2004 Update,&quot; <i>J Allergy Clin Immunol</i>, 2005, 115(1):34-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/15637545/pubmed\" target=\"_blank\" id=\"15637545\">15637545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/25711134/pubmed\" target=\"_blank\" id=\"25711134\">25711134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salmun LM, Herron JM, Banfield C, et al, &ldquo;The Pharmacokinetics, Electrocardiographic Effects, and Tolerability of Loratadine Syrup in Children Aged 2 to 5 Years,&rdquo; <i>Clin Ther</i>, 2000, 22(5):613-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/10868558 /pubmed\" target=\"_blank\" id=\"10868558 \">10868558 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. <i>N Engl J Med</i>. 1994; 9;330(23):1663-1670.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/7909915/pubmed\" target=\"_blank\" id=\"7909915\">7909915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &quot;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&quot; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy</i>. 2014;69(7):868-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loratadine-pediatric-drug-information/abstract-text/24785199/pubmed\" target=\"_blank\" id=\"24785199\">24785199</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12563 Version 245.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F190023\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F190024\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059881\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059874\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F190002\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189988\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059886\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F190019\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059885\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6699703\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F190073\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F190007\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189992\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F28473558\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F190063\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189997\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F190020\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12881433\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059880\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189991\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F190006\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F190009\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F190012\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12563|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=loratadine-drug-information\" class=\"drug drug_general\">Loratadine: Drug information</a></li><li><a href=\"topic.htm?path=loratadine-patient-drug-information\" class=\"drug drug_patient\">Loratadine: Patient drug information</a></li></ul></div></div>","javascript":null}